Pfizer Inc. $PFE Shares Purchased by VeraBank N.A.

VeraBank N.A. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 27.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,568 shares of the biopharmaceutical company’s stock after acquiring an additional 8,625 shares during the period. VeraBank N.A.’s holdings in Pfizer were worth $983,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the first quarter valued at about $27,000. Curio Wealth LLC raised its holdings in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer during the 2nd quarter worth approximately $29,000. Finally, WPG Advisers LLC acquired a new stake in Pfizer in the first quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on PFE. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Bank of America increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.18.

Pfizer Stock Down 0.1%

PFE stock opened at $24.40 on Tuesday. The firm has a market cap of $138.73 billion, a price-to-earnings ratio of 12.98, a PEG ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The firm has a fifty day moving average price of $24.74 and a two-hundred day moving average price of $24.39. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.